drugset
Drugs / MVA HIV-B
last change Jul 2023 re-read 2 minutes ago

MVA HIV-B

also known as ANRS MVA HIV-B · ANRS MVA HIV-B (MVATG17401) vaccine candidate · MVATG17401

Vaccine

Developed for
HIV infectious disease
Investigated by
ANRS, Emerging Infectious Diseases · Centre Hospitalier Universitaire Vaudois · European Commission · European Georges Pompidou Hospital · Henri Mondor University Hospital · Imperial College London
+16 more · Institut d'Investigacions Biomèdiques August Pi i Sunyer · Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS · Medical Research Council · Saint-Louis Hospital, Paris, France · Swiss Government · University Medical Center Hamburg-Eppendorf · Chelsea and Westminster Hospital, UK · Erasmus Medical Center · EuroVacc Foundation · European AIDS Treatment Group (EATG) · FIT Biotech Ltd. · Fred Hutchinson Cancer Center · Hospital Clinic of Barcelona · University College London Hospitals · University College, London · University of Liverpool

Trials 3 · a red edge is where a trial was stopped

today NCT04120415 · Ph 2 NCT02972450 · Ph 1/2 NCT02038842 · Ph 1/2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT02972450 Feb → Jul 2019 HIV infectious disease ANRS, Emerging Infectious Diseases Terminated No outcome recorded
Phase 1/2 NCT02038842 Mar 2014 → Oct 2015 HIV infectious disease ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04120415 Jun 2022 → Jul 2023 HIV infectious disease ANRS, Emerging Infectious Diseases Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as MVA HIV-B “0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8.” NCT04120415 ↗
2

NCT02038842 ↗

NCT02972450 ↗
Known as ANRS MVA HIV-B “0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm.” NCT02972450 ↗
Known as ANRS MVA HIV-B (MVATG17401) vaccine candidate “ANRS MVA HIV-B (MVATG17401) vaccine candidate” NCT02038842 ↗
Known as MVATG17401 “MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;” NCT02038842 ↗
Modality Vaccine “In this phase I/II multi-arm trial, three vaccine candidates were used as prime or boost: modified vaccinia Ankara (MVA) HIV-B (coding for Gag, Pol, Nef); HIV LIPO-5 (five...” PMID 35613727 ↗ May 2022
Route Intramuscular “MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;” NCT02038842 ↗